Recent advances in targeted strategies for triple-negative breast cancer

Area of Science:

• Oncology
• Medical Research

Background:

• Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype lacking estrogen receptor, progesterone receptor, and HER2 expression.
• Current chemotherapy options for TNBC have limited effectiveness, necessitating urgent development of novel therapeutic strategies.

Purpose of the Study:

• To summarize recent advances in targeted therapy and immunotherapy for TNBC.
• To provide a reference for future development of individualized treatment approaches for TNBC patients.

Main Methods:

• Review of emerging targeted therapeutic strategies including PI3K/AKT/mTOR inhibitors, EGFR inhibitors, Notch inhibitors, PARP inhibitors, and antibody-drug conjugates.
• Exploration of immune checkpoint inhibitors (e.g., pembrolizumab, atezolizumab, durvalumab) in clinical settings for TNBC.

Main Results:

• Multiple targeted therapies are being developed based on specific TNBC molecular pathways.
• Immunotherapies, particularly immune checkpoint inhibitors, are under extensive clinical investigation for TNBC treatment.

Conclusions:

• Significant progress has been made in developing targeted therapies and immunotherapies for TNBC.
• These advancements offer potential for more personalized and effective treatment strategies for patients with triple-negative breast cancer.